Therefore, a useful tumor model of ERα+ breast cancer resistant to anti-hormone therapies at skeletal sites, should consider the interactions between the bone microenvironment, the immune system and ERα+ mammary tumor cells. This evidence concerns the gene ESR1 and neoplasm.